New arthritis drug enters early safety testing
NCT ID NCT06628206
First seen Nov 20, 2025 · Last updated May 17, 2026 · Updated 23 times
Summary
This early-stage study tests a new oral drug, LPX-TI641, in 48 adults with rheumatoid arthritis or psoriatic arthritis. The main goal is to see if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through the body. This is a Phase 1 trial, so it focuses on safety, not yet on how well the drug treats the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITINGAmman, ST B204, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.